Brean Murray Carret & Co Revises EPS Estimates Of Gilead


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


According to Brean, Gilead Sciences (NASDAQ: GILD), EPS estimates have changed. Brean reported a change in EPS estimates from $3.91 to $3.65 for FY11 and from $4.40 to $4.22 for FY12. Rating is set to Buy with a PT of $52.Gilead closed yesterday at $35.34.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorAnalyst RatingsBiotechnologyBrean Murray Carret & CoHealth Care